Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Release Date: November 25, 2025

Expiration Date: November 25, 2026

Activity Overview

Consolidation and maintenance therapy are crucial in helping patients with small cell lung cancer (SCLC) retain the gains they made with first-line therapy. Immunotherapy options have demonstrated a benefit in both of these settings. Bispecific antibodies and antibody-drug conjugates are also improving outcomes as maintenance or second-line therapies.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from an Association of Cancer Care Centers virtual webcast series on current and emerging therapies in limited-stage and extensive-stage SCLC. This unique and engaging multimedia activity is ideal for the community-based clinician. It focuses on clinical trial data of targeted and immunotherapy. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.

Target Audience

This educational program is primarily directed toward community-based oncologists involved in the treatment of SCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss current trial data describing novel strategies for the management of limited- and extensive-stage small cell lung cancer (SCLC)
• Plan strategies to prevent and proactively manage treatment-related adverse events in patients with SCLC
• Apply clinical trial evidence supporting the efficacy and safety of SCLC treatment strategies to optimally manage patients with SCLC in the second- and subsequent-line setting